KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

The intricate landscape of medical research continues to unveil groundbreaking approaches to managing chronic joint health ...

A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...